MaxCyte Inc
LSE:MXCT
Income Statement
Earnings Waterfall
MaxCyte Inc
Revenue
|
41.3m
USD
|
Cost of Revenue
|
-4.7m
USD
|
Gross Profit
|
36.5m
USD
|
Operating Expenses
|
-84.8m
USD
|
Operating Income
|
-48.3m
USD
|
Other Expenses
|
10.4m
USD
|
Net Income
|
-37.9m
USD
|
Income Statement
MaxCyte Inc
Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
Revenue |
39
N/A
|
41
+6%
|
42
+1%
|
44
+5%
|
41
-7%
|
41
-1%
|
38
-6%
|
41
+9%
|
|
Gross Profit | |||||||||
Cost of Revenue |
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
|
Gross Profit |
35
N/A
|
37
+6%
|
37
+0%
|
39
+5%
|
36
-8%
|
35
-2%
|
33
-6%
|
37
+10%
|
|
Operating Income | |||||||||
Operating Expenses |
(51)
|
(57)
|
(63)
|
(67)
|
(73)
|
(76)
|
(80)
|
(85)
|
|
Selling, General & Administrative |
(36)
|
(41)
|
(43)
|
(44)
|
(48)
|
(50)
|
(53)
|
(57)
|
|
Research & Development |
(13)
|
(15)
|
(17)
|
(20)
|
(22)
|
(23)
|
(24)
|
(24)
|
|
Depreciation & Amortization |
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
|
Operating Income |
(16)
N/A
|
(20)
-27%
|
(26)
-26%
|
(27)
-7%
|
(36)
-33%
|
(41)
-12%
|
(47)
-15%
|
(48)
-3%
|
|
Pre-Tax Income | |||||||||
Interest Income Expense |
(0)
|
0
|
2
|
4
|
6
|
8
|
10
|
10
|
|
Pre-Tax Income |
(16)
N/A
|
(20)
-24%
|
(24)
-19%
|
(24)
+0%
|
(30)
-29%
|
(33)
-7%
|
(37)
-15%
|
(38)
-1%
|
|
Net Income | |||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(16)
|
(20)
|
(24)
|
(24)
|
(30)
|
(33)
|
(37)
|
(38)
|
|
Net Income (Common) |
(16)
N/A
|
(20)
-24%
|
(24)
-19%
|
(24)
+0%
|
(30)
-29%
|
(33)
-7%
|
(37)
-15%
|
(38)
-1%
|
|
EPS (Diluted) |
-0.17
N/A
|
-0.2
-18%
|
-0.23
-15%
|
-0.23
N/A
|
-0.3
-30%
|
-0.32
-7%
|
-0.37
-16%
|
-0.37
N/A
|